Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Non-Hodgkin lymphoma (NHL) remains the most common type of cancer and a leading cause of mortality in people who are living with human immunodeficiency virus (HIV).1 This is despite a marked decrease in the incidence of HIV-associated NHL (HIV–NHL) following the introduction of combination antiretroviral therapy (ART) in the mid-1990s.2 In contrast, the incidence of Hodgkin lymphoma (HL) increased slightly but has remained stable since 2000.1 Compared with the age- and gender-matched general population, the incidences of HIV–NHL and HIV-associated HL (HIV–HL) are increased ∼10- to 20-fold.
Authors
- Éric Oksenhendler (ORCID: https://orcid.org/0000-0001-8588-7138)
- Simon Collins (ORCID: https://orcid.org/0000-0002-3537-2432)
- Silvia Montoto (ORCID: https://orcid.org/0000-0002-3006-9725)
- Uta Brunnberg
- Philipp Schommers (ORCID: https://orcid.org/0000-0003-3375-6800)
- Kate Cwynarski (ORCID: https://orcid.org/0000-0001-9936-3431)
- Marcus Hentrich (ORCID: https://orcid.org/0000-0001-5622-348X)
- Mariana Bastos‐Oreiro (ORCID: https://orcid.org/0000-0002-9431-4646)
- M. J. Kersten
- Bastian von Tresckow (ORCID: https://orcid.org/0000-0003-1410-4487)
- Alessandro Re (ORCID: https://orcid.org/0000-0003-1156-6395)
- Chiara M. Cattaneo (ORCID: https://orcid.org/0000-0003-0031-3237)
- José‐Tomás Navarro (ORCID: https://orcid.org/0000-0001-9101-6013)
- Mark Bower (ORCID: https://orcid.org/0000-0002-4077-6351)
- C. Buske
- Caroline Besson (ORCID: https://orcid.org/0000-0003-4364-7173)
- M. Dreyling
- Josep‐María Ribera (ORCID: https://orcid.org/0000-0003-1042-6024)
- Kai Hübel (ORCID: https://orcid.org/0000-0002-7958-4664)
- Igor Aurer (ORCID: https://orcid.org/0000-0001-6175-4277)
- Andrew Davies (ORCID: https://orcid.org/0000-0002-7048-2709)
- Christian Hoffmann (ORCID: https://orcid.org/0000-0002-1082-8093)
- Alessia Dalla Pria (ORCID: https://orcid.org/0000-0002-7421-6002)
Institutions
- Goethe University Frankfurt (DE)
- Universitat Autònoma de Barcelona (ES)
- University College Hospital (GB)
- St Bartholomew's Hospital (GB)
- University Hospital Centre Zagreb (HR)
- Inserm (FR)
- University of Zagreb (HR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Barts Health NHS Trust (GB)
- Université Paris-Saclay (FR)
- Hospital General Universitario Gregorio Marañón (ES)
- Josep Carreras Leukaemia Research Institute (ES)
- Assistance Publique – Hôpitaux de Paris (FR)
- Red Cross Hospital (GR)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Institut Català d'Oncologia (ES)
- Infektionsmedizinisches Centrum Hamburg (DE)
- Essen University Hospital (DE)
- University Hospital Frankfurt (DE)
- Chelsea and Westminster Hospital (GB)
- Hôpital Saint-Louis (FR)
- Amsterdam University Medical Centers (NL)
- University Hospital Cologne (DE)
- Centre Hospitalier de Versailles (FR)
- University College London (GB)
- University of Duisburg-Essen (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1016/j.annonc.2024.06.003
- Citations
- 9
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.54
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Gilead Sciences
- Celgene
- ViiV Healthcare
- Jazz Pharmaceuticals
- Atara Biotherapeutics
- BeiGene
- Recordati Rare Diseases
- Incyte
- European Society for Medical Oncology
- Swedish Orphan Biovitrum
- EUSA Pharma
- Kite Pharma
- Cilag